U.S. FDA approves first generic drug for asthma and COPD treatment
Category: #health  By Mateen Dalal  Date: 2019-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves first generic drug for asthma and COPD treatment

The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases.

The U.S. Food and Drug Administration recently announced that it has approved the first generic version of Advair Diskus for asthma treatment in patients aged four years and above. Approval has been granted for 500 mcg/50 mcg, 250 mcg/50 mcg and 100 mcg/50 mcg doses of the generic drug, which is indicated for twice daily treatment of patients suffering from chronic obstructive pulmonary disease which include emphysema and bronchitis besides being approved for asthma.

The newly approved generic drug is reported to contain long-acting beta(2)-adrenergic agonist (LABA) and corticosteroid which help in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and treatment of airflow obstruction. For the record, this is a complex drug-device combination medical product and no generic medical product of the same kind has won an FDA approval before this.

Janet Woodcock, MD and director of Center for Drug Evaluation and Research, FDA, has been reported by a press release to say that the approval of the generic drug product for the most frequently prescribed asthma and COPD inhalers in the country, demonstrates FDA’s commitment towards advancing access to high quality yet low-cost generic alternatives. She added that people with COPD and asthma understand and experience the critical importance of being able to afford the treatment to feel healthy and the recent approval is yet another step towards benefitting those who rely on this drug besides increasing market competition.

For the record, 26 million people in the U.S., which includes children as well, suffer from asthma while an additional 16 million people have to fight COPD. Availability of generic medicines for these disorders are a basic benefit that the citizens will be able to access through the recent approval.

According to sources, the FDA approves of generic drugs once it is satisfied that the generic drug is as effective and as safe as the brand name drug. For this approval the generic drug has to undergo rigorous approval standards. The generic drug also has to maintain the same packaging and manufacturing standards as the branded drug.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...